Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer

Actinium Pharmaceuticals will present early first-in-human Phase 1 data for ATNM-400, its non-PSMA Actinium-225 radioconjugate, in an oral presentation at the EANM annual congress in Vienna, October 17-21, 2026. The Phase 1 dose-escalation study in metastatic castration-resistant prostate cancer uses Zirconium-89-labeled ATNM-400 to assess safety, biodistribution, and dosimetry, informing therapeutic Actinium-225 dosing.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.